Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study

High tumor mutational burden (TMB-H) correlates with improved immunotherapy response. We assessed atezolizumab 1,200 mg every 3 weeks for TMB-H tumors from MyPathway (NCT02091141), a phase IIa multibasket study. One hundred twenty-one patients had advanced solid tumors with TMB ≥10 mut/Mb by any Cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedman, Claire F., Hainsworth, John D., Kurzrock, Razelle, Spigel, David R., Burris, Howard A., Sweeney, Christopher J., Meric-Bernstam, Funda, Wang, Yong, Levy, Jonathan, Grindheim, Jessica, Shames, David S., Schulze, Katja, Patel, Arisha, Swanton, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394388/
https://www.ncbi.nlm.nih.gov/pubmed/34876409
http://dx.doi.org/10.1158/2159-8290.CD-21-0450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394388/
https://www.ncbi.nlm.nih.gov/pubmed/34876409
http://dx.doi.org/10.1158/2159-8290.CD-21-0450

Ejemplares similares